Starpharma's drug delivery program with Lilly advances

Starpharma's drug delivery program with Lilly advances

19 December 2011

Melbourne, Australia: 19 December 2011, Starpharma (ASX: SPL; OTCQX SPHRY) today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.

Starpharma has a number of projects underway with Lilly to improve the delivery of small molecule and protein-based pharmaceuticals using Starpharma's dendrimer technology.

Based on results in the companies' dendrimer-drug conjugate program, the parties have agreed to an expanded development program, incorporating further in vivo studies followed by clinical testing, as well as potential commercial terms should a product ultimately be brought to market.

The nature of the product and the associated commercial terms have not been disclosed due to confidentiality restrictions.

"We are pleased to be able to report progress in our collaborations with Lilly," said Dr Jackie Fairley, CEO Starpharma. "We value the opportunity to advance our relationship with Lilly with these new arrangements."

 

 

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.